Table 1. Treo indicates treosulfan; Clo,... | American Society of Hematology

Table 1.

Retrospective studies reporting outcomes after allogeneic SCT in patients with high-risk AML/MDS using recently developed RIC regimens

Retrospective studies reporting outcomes after allogeneic SCT in patients with high-risk AML/MDS using recently developed RIC regimens

Treo indicates treosulfan; Clo, clofarabine; REF, refractory; NHL, non-Hodgkin lymphoma; and ALL, acute lymphoblastic leukemia.

This Feature Is Available To Subscribers Only

Sign In or Create an Account